Klow Stack

The Klow Stack (KLOW) is a peptide blend of four known, individually researched peptides combined in a single vial. It focuses on regeneration, tissue repair and systemic anti-inflammation. Evidence level 2 (experimental): no standalone human trials exist for the combination itself.

What is in the Klow Stack?

The recipe is now openly disclosed by essentially every compounder - it is no longer proprietary in any meaningful sense. The standard is an 80 mg vial in a 50 / 10 / 10 / 10 split:

• GHK-Cu (50 mg): copper-binding tripeptide (Gly-His-Lys), collagen and remodeling signaling.
• BPC-157 (10 mg): pentadecapeptide from gastric juice, studied preclinically for angiogenesis and soft-tissue repair.
• TB-500 (10 mg): synthetic fragment of thymosin-β4, studied for cell migration and vascular remodeling.
• KPV (10 mg): C-terminal tripeptide of α-MSH (Lys-Pro-Val), anti-inflammatory via NF-κB inhibition.

Some compounders deviate slightly in the ratios; the components themselves are consistent across vendors.

How does Klow differ from the Glow Stack?

The Glow Stack contains the same three regenerative peptides (GHK-Cu + BPC-157 + TB-500) but no KPV. KPV is the actual difference: it adds a systemic, NF-κB-driven anti-inflammatory axis on top of the regenerative base. Users who want inflammation control (skin, mucosa, systemic) in addition to regeneration usually end up on KLOW.

Who is Klow intended for?

• Tissue repair: tendons, muscle, post-procedure recovery.
• Skin and connective tissue: collagen support, scar healing.
• Inflammation modulation: NF-κB inhibition via KPV, particularly epithelial/mucosal.
• General regeneration: user reports, no validated clinical indication.

What does the evidence say?

Evidence is, frankly, thin: level 2, experimental. The individual components (GHK-Cu, BPC-157, TB-500, KPV) are solidly studied preclinically; a standalone clinical trial of the four-component combination does not yet exist. All KLOW-specific effect claims are based on component-data extrapolation plus anecdotal reports.

Important note on name confusion

Various online sources claim KLOW contains "the Klotho protein", blocks apoptosis or extends lifespan by 15-20%. Those statements refer to endogenous α-Klotho, a bona fide longevity protein with documented anti-apoptotic and neuroprotective activity. The KLOW peptide blend has nothing to do with it: it contains no Klotho protein and no Klotho sequence. The name overlap (reportedly a nod to Klotho / Clotho, the Greek Fate who spins the thread of life) is purely semantic.

Regulatory status

KLOW is not an approved drug (no FDA/EMA approval for the combination). It is supplied by compounding pharmacies as a "research use" / off-label preparation. Use only under medical supervision and with realistic expectations of the evidence.